Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 2/20 | 0.49 |
| ▸ | FNTB | P49356 | 2/20 | 0.49 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8776950 | 1.00 | CA2 (0.64) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL5438740 | 1.00 | CA2 (0.64) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL28881894 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL28881895 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| Water SCHEMBL4387175 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| Water SCHEMBL4387169 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| Water SCHEMBL4387164 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL10977896 | 0.89 | MAPT (0.54) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL27508575 | 0.89 | CA2 (0.67) | CA2CA1MAPTNPC1TP53 | |
| SCHEMBL5699610 | 0.89 | CA2 (0.67) | CA2CA1MAPTNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115138353-B | Carbon source coated monolithic catalyst and preparation method and application thereof | 横店集团东磁股份有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-108147977-B | Preparation method of N-p-aminobenzoyl-L-glutamic acid | 江苏尚莱特医药化工材料有限公司 | 2020-09-25 | — | — | CN | claimed |
| CN-110668968-A | Preparation method of p-aminobenzoyl glutamic acid | 涉县津东经贸有限责任公司 | 2020-01-10 | — | — | CN | claimed |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-17 | — | — | US | claimed |
| US-4505788-A | FROM P-NITROBENZOYL GLUTAMIC ACID | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-03-19 | — | — | US | claimed |
| US-3941776-A | RACEMIZATION OF AMINOLACTAM COMPOUNDS | ALLIED CHEMICAL CORPORATION (US) | 1976-03-02 | — | — | US | claimed |
| JP-60234986-A | — | — | None | — | — | JP | disclosed |
| JP-59204158-A | — | — | None | — | — | JP | disclosed |
| JP-59222592-A | — | — | None | — | — | JP | disclosed |
| CN-119118861-A | Preparation method and application of methotrexate intermediate | 成都精西药业有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-115138353-B | Carbon source coated monolithic catalyst and preparation method and application thereof | 横店集团东磁股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-115138353-B | Carbon source coated monolithic catalyst and preparation method and application thereof | 横店集团东磁股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-116920839-A | Carbon-coated porous monolithic catalyst and preparation method thereof | 横店集团东磁股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-4505788-A | FROM P-NITROBENZOYL GLUTAMIC ACID | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-03-19 | — | — | US | disclosed |
| JP-S59222592-A | PRODUCTION OF P-AMINOBENZOYL GLUTAMIC ACID | TAKEDA CHEM IND LTD | 1984-12-14 | — | — | JP | disclosed |
| JP-S59204158-A | PRODUCTION OF P-AMINOBENZOYLGLUTAMIC ACID | DAICEL CHEM IND LTD | 1984-11-19 | — | — | JP | disclosed |
| EP-0031237-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTI-CANCER AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-17 | — | — | EP | disclosed |
| US-4447608-A | ANTITUMOR AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-05-08 | — | — | US | disclosed |
| EP-0031237-A1 | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-07-01 | — | — | EP | disclosed |
| US-4191765-A | 1-Aryloxy-2-hydroxy-3-aminopropanes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | CPN1, AKR1C3, AHCY | CA2 361/4885CA1 113/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.